INVAInnoviva, Inc.
Price
+11%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, undemanding price, growth steady, the market undecided.
Innoviva, Inc. (“Innoviva”, the “Company”, the “Registrant” or “we” and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/vilanterol, “FF/VI”) and ANORO® ELLIPTA® (umeclidinium bromide/vilanterol, “UMEC/VI”).
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Innoviva, Inc. (INVA) reported revenue of $120M in Q2 2026 (quarter ended Jun 30, 2026), up 19% from the same quarter a year earlier. That came with a gross margin of 76% and net loss of $83M. For the full year FY2025, revenue was $411M (+15% year on year) and net income $271M. Its largest product in Q2 2026 was Royalty at $56M, 46% of the disclosed total, well ahead of Xacduro at 18%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress.Earnings release · press release
- May 18, 2026On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc. (the “Board” and the “Company”), in order to focus on the growth of Syndeio BioSciences Inc. (“Syndeio”), where Mr. Small serves as Chief Executive Officer and Mr. DiPaolo is expected to assume …Director or officer change · Form 8-K
- May 6, 2026Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $121.4MThe company’s own SEC segment disclosure.
- Royalty$56.3M46%
- Xacduro$22.4M18%
- Giapreza$22.3M18%
- License And Other$11.5M9%
- Xerava$6.7M6%
- Cost Reimbursement$1.8M1%
- Other (1)$351.0K0%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.